The siRNA knockdown could reduce the GSK-3β RNA expression to 30% (HCT116 31.92 ± 7.92%, LOVO 28.52 ± 7.42%) of the control group in the colorectal cancer HCT116 and LOVO cell lines while the protein level expression is also significant downregulated (Figures 3(a) and 3(b)). This evidence concerns the gene GSK3B and colorectal cancer.